Application of encapsulated cell technology for retinal degenerative diseases
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Ophthalmic disorders represent a rapidly growing disease area that is associated with the ageing population. Their sight is threatened by age-related macular degeneration, diabetic retinopathy, glaucoma and/or retinitis pigmentosa (RP). Few effective treatments for these disorders are available at present, in part due to lack of effective delivery of therapeutic molecules to the retina. Encapsulated cell technology (ECT) allows the controlled, continuous and long-term administration of protein drugs in the eye, where therapeutic agents are needed, and does not subject the host to the systemic exposure. Furthermore, the implants can be retrieved, providing an added level of safety. Ciliary neurotrophic factor (CNTF) has been shown to protect the retina from degeneration in 13 animal models, and ECT-based delivery of CNTF protected photoreceptors in the rcd1 dog model of RP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845
The epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
The Grading and Prevalence of Macular Degeneration in Chesapeake Bay Watermen
Bressler, N. M. (1989) · Archives of Ophthalmology · doi:10.1001/archopht.1989.01070010869032 · Cited by 251 · cited 1×
“Ophthalmic disorders represent a rapidly growing disease area that is associated with the ageing population [1-6].”
BackgroundAge-Specific Causes of Bilateral Visual Impairment
Weih, L. M. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.2.264 · Cited by 191 · cited 1×
“Their sight is threatened by age-related macular degeneration (AMD) [7-9], diabetic retinopathy [10-14], glaucoma [15-18] and/or retinitis pigmentosa (RP) [19-22].”
Background
Cited by
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Current and future ophthalmic drug delivery systems
del Amo, E. M., & Urtti, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.002 · Cited by 414
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 316
Zhang, K., Hopkins, J. J., Heier, J. S., Birch, D. G., Halperin, L. S., Albini, T. A., Brown, D. M., Jaffe, G. J., Tao, W., & Williams, G. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018987108 · Cited by 310
Self-citationFibrosis and diseases of the eye
Friedlander, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31030 · Cited by 299
Metadata
- Authors
- Tao, W.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2006-06-29
- Volume
- 6
- Issue
- 7
- Pages
- 717-726
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2128461993
- Cited by
- 109
- References
- 5
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Application of encapsulated cell technology for retinal degenerative diseases. https://app.cochat.ai/papers/10.1517/14712598.6.7.717
- The paper
- Tao, W. (2006). Application of encapsulated cell technology for retinal degenerative diseases. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.6.7.717
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.